Findings published in JAMA Dermatology suggested that clinically important increases in melanoma risk in patients treated with biologic therapy for common inflammatory diseases cannot yet be ruled out.

However, the researchers also indicated that future studies with larger patient numbers that adjust for key risk factors are necessary to resolve the issue of long-term safety of biologic therapy.